Thematic ETF issuer ETFMG has launched the ETFMG Treatments, Testing and Advancements ETF (GERM), which seeks to answer investor demand for direct exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. The first-to-market methodology behind the Fund focuses on the advancements in the infectious disease sub-sector of biotech with targeted exposure to US-listed companies at the forefront of R&D, vaccines, therapies and testing technologies.
GERM provides access to both established providers as well as the “unsung heroes” of the biotech and life sciences market. The frequency and diversity of disease outbreaks, similar to COVID-19, have grown steadily for the past 30 years.
“Our global health depends a great deal on innovation and discovery that will address how to prevent further infection with enhanced immune therapies or vaccines,” says Reynold A Panettieri, Jr, MD, Professor of Medicine, Vice Chancellor for Translational Medicine and Science at Rutgers University, and Director of the Institute for Translational Medicine and Science. “GERM offers a unique approach that embraces cutting-edge technologies through cooperativity among Big/Small Pharma and biotech that can nimbly leverage discoveries and translate them into commercialised and impactful assets.”
“GERM represents an investment theme that is much more than topical, it provides unique exposure to a previously underrepresented growth sector within biotech. We are excited to bring this product to US investors,” says Sam Masucci, CEO and Founder of ETFMG.
